At the recent American Association for Cancer Research (AACR) Special Conference on Advances in Pancreatic Cancer Research, researchers from Cellectar Biosciences Inc. presented preclinical data on [225Ac]CLR-121225 (CLR-225), a novel actinium-based radio conjugate alpha-emitter for treatment in hypoxic pancreatic ductal adenocarcinoma.
Genetic mutations are the primary cause of most rare diseases. Although each condition affects a small fraction of the population, the global impact is significant, with an estimated 300 million individuals affected worldwide. A large proportion of pathogenic missense variants – estimated at 40%-60% – cause rare diseases by impairing protein stability. This underscores protein restoration as a promising therapeutic strategy.
Pharma companies are collaborating to boost the power of artificial intelligence (AI) in drug discovery by allowing access to proprietary structural data to train a large language model. Each of the partners is contributing data from several thousand experimentally determined protein:ligand interactions, creating one of the most diverse datasets and the richest chemistry assembled to date for model training.
Convalife Pharmaceuticals Co. Ltd. and Zhejiang Convalife Pharmaceutical Co. Ltd. have described benzoselenazepine compounds reported to be useful for the respiratory syncytial virus (RSV) infection.
Beijing DP Technology Co. Ltd. has divulged proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase-binding moiety covalently bonded to a Myc proto-oncogene protein (c-Myc)-targeting moiety through a linker reported to be useful for the treatment of cancer, viral infections, and cardiovascular, immunological and cerebrovascular disorders.
The University of California has synthesized proprotein convertase subtilisin/kexin-type 9 (PCSK9) inhibitors reported to be useful for the treatment of cancer, atherosclerosis and stroke.
Hyundai Pharmaceutical Co. Ltd. has disclosed ubiquitin carboxyl-terminal hydrolase 1 (USP1) inhibitors potentially useful for the treatment of cancer.
Neuromyelitis optica spectrum disorder (NMOSD) is neuroinflammatory disease characterized by optic neuritis and myelitis with presence of anti-aquaporin-4 (AQP4) antibodies. Satralizumab is an anti-IL-6 receptor (IL-6R) humanized antibody approved for preventing relapses in NMOSD (AQP4 IgG positive) in adults and children in Japan.
Researchers at Alligator Bioscience AB and Lund University have developed a bispecific therapeutic antibody, ATOR-4066, that simultaneously targets the immune cell receptor CD40 and the tumor antigen CEACAM5.
RSS
